373 related articles for article (PubMed ID: 31092051)
1. Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis.
Liu J; Wang LN
Expert Rev Neurother; 2019 Jun; 19(6):475-480. PubMed ID: 31092051
[No Abstract] [Full Text] [Related]
2. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Chan M; Ghassemi A
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):106-112. PubMed ID: 26420886
[TBL] [Abstract][Full Text] [Related]
3. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MG; Tabet N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
Liu J; Wang LN; Jia JP
Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005
[TBL] [Abstract][Full Text] [Related]
5. Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Manolopoulos A; Andreadis P; Malandris K; Avgerinos I; Karagiannis T; Kapogiannis D; Tsolaki M; Tsapas A; Bekiari E
Am J Alzheimers Dis Other Demen; 2019 Aug; 34(5):281-289. PubMed ID: 30987435
[TBL] [Abstract][Full Text] [Related]
6. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Isaac MG; Clark AR; Rusted J; Tabet N
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD002854. PubMed ID: 23152215
[TBL] [Abstract][Full Text] [Related]
7. Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease.
Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Au Y; Chan M; Ghassemi A
BMC Neurosci; 2021 Aug; 22(1):49. PubMed ID: 34362303
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of blood derivatives therapy in Alzheimer's disease: a systematic review and meta-analysis.
Fei Z; Pan B; Pei R; Chen Z; Du X; Cao H; Li C
Syst Rev; 2022 Nov; 11(1):256. PubMed ID: 36443888
[TBL] [Abstract][Full Text] [Related]
9. Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Matsunaga S; Kishi T; Annas P; Basun H; Hampel H; Iwata N
J Alzheimers Dis; 2015; 48(2):403-10. PubMed ID: 26402004
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Okuya M; Matsunaga S; Ikuta T; Kishi T; Iwata N
J Alzheimers Dis; 2018; 66(4):1379-1387. PubMed ID: 30452419
[TBL] [Abstract][Full Text] [Related]
11. Effects of saffron (Crocus sativus L.) on cognitive function. A systematic review of RCTs.
Avgerinos KI; Vrysis C; Chaitidis N; Kolotsiou K; Myserlis PG; Kapogiannis D
Neurol Sci; 2020 Oct; 41(10):2747-2754. PubMed ID: 32445136
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulins for Alzheimer's disease.
Puli L; Tanila H; Relkin N
Curr Alzheimer Res; 2014; 11(7):626-36. PubMed ID: 25115546
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
14. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials.
Kishi T; Matsunaga S; Oya K; Ikuta T; Iwata N
Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26091818
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
Cao B; Rosenblat JD; Brietzke E; Park C; Lee Y; Musial N; Pan Z; Mansur RB; McIntyre RS
Diabetes Obes Metab; 2018 Oct; 20(10):2467-2471. PubMed ID: 29790638
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E for Alzheimer's disease and mild cognitive impairment.
Isaac MG; Quinn R; Tabet N
Cochrane Database Syst Rev; 2008 Jul; (3):CD002854. PubMed ID: 18646084
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil.
Pisani S; Mueller C; Huntley J; Aarsland D; Kempton MJ
Int J Geriatr Psychiatry; 2021 Oct; 36(10):1471-1487. PubMed ID: 34490652
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Fujino T; Yamada T; Asada T; Tsuboi Y; Wakana C; Mawatari S; Kono S
EBioMedicine; 2017 Mar; 17():199-205. PubMed ID: 28259590
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
